M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Head and Neck Squamous Cell Carcinoma
Advanced Ovarian Clear Cell Adenocarcinoma
Chondrosarcoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Pathologic Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8

Interventions: Drug: Glutaminase-1 Inhibitor IACS-6274
Biological: Bevacizumab
Drug: Capivasertib
Drug: Paclitaxel

First Posted Date: 2021-09-10

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT05039801

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Phase 1

Active, not recruiting

Conditions: Colon Cancer
Resected Stage

Interventions: Drug: Cetuximab
Drug: Expanded CB-NK cells
Drug: Fludarabine phosphate
Drug: Cyclophosphamide

First Posted Date: 2021-09-10

Last Posted Date: 2024-12-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT05040568

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Phase 1

Terminated

Conditions: Breast Inflammatory Carcinoma
Recurrent Breast Inflammatory Carcinoma
Stage IV Breast Inflammatory Carcinoma

Interventions: Drug: Eribulin Mesylate
Drug: Grapiprant

First Posted Date: 2021-09-10

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT05041101

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment

Recruiting

Conditions: Pneumonia
Hematopoietic System--Cancer
Pulmonary

First Posted Date: 2021-09-10

Last Posted Date: 2024-08-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT05041140

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Phase 2

Withdrawn

Conditions: Liver Cancer
Hepatocellular Carcinoma

Interventions: Drug: Cabozantinib
Drug: Nivolumab

First Posted Date: 2021-09-10

Last Posted Date: 2023-05-12

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05039736

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Early Phase 1

Recruiting

Conditions: Advanced Gastric Adenocarcinoma
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Metastatic Gastroesophageal Junction Adenocarcinoma
Pathologic Stage III Gastric Cancer AJCC v8
Pathologic Stage IIIA Gastric Cancer AJCC v8
Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIB Gastric Cancer AJCC v8
Pathologic Stage IIIC Gastric Cancer AJCC v8
Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8

Interventions: Drug: Lenvatinib
Biological: Pembrolizumab

First Posted Date: 2021-09-10

Last Posted Date: 2025-01-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT05041153

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia

Phase 1

Recruiting

Conditions: Chronic Myelomonocytic Leukemia-2
Chronic Myelomonocytic Leukemia-1
Chronic Myelomonocytic Leukemia
Myelodysplastic/Myeloproliferative Neoplasm

Interventions: Drug: Decitabine
Biological: Tagraxofusp-erzs

First Posted Date: 2021-09-09

Last Posted Date: 2024-11-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT05038592

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

Not Applicable

Recruiting

Conditions: Clinical Stage IV Gastric Cancer AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IVB Gastric Cancer AJCC v8
Metastatic Rectal Carcinoma
Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8
Metastatic Gastric Carcinoma
Metastatic Malignant Digestive System Neoplasm
Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8